China’s lower cost CAR-t therapy attracts cancer patients
Summary and headline written by AI from the source article. How we work
Michael Walters of New Zealand received successful CAR-T therapy in Shanghai after previous treatments in his home country failed. He paid less than half the price quoted by a hospital in Melbourne for the same treatment.
CAR-T therapy, which modifies a patient’s immune cells to fight cancer, is significantly more affordable in China, costing between $150,000 and $230,000 compared to $550,000 to $850,000 in the United States.
China currently approves nine CAR-T products, more than any other nation, and can process and deliver engineered cells to patients within days. This availability is due to China’s rapid industrialization of the therapy. While price is a major factor, experts note the world is better at moving therapies across borders than ensuring consistent care for patients who seek treatment abroad. Regulators emphasize the importance of clear explanations for patients regarding approved uses, clinical trials, and aftercare plans.
However, early remission does not guarantee better overall care, as patients who travel for treatment are a select group. Additionally, maintaining long-term care is crucial, as CAR-T therapy can cause severe side effects and requires ongoing monitoring, which can be difficult for patients returning home without easily accessible records or a clear follow-up plan. Experts suggest establishing shared-care agreements, transparent pricing, and cross-border registries to improve patient outcomes and track long-term results.
